NeoGenomics, Inc. (NEO) vs YD Bio Limited Ordinary Shares (YDES)

A side-by-side comparison of NeoGenomics, Inc. and YD Bio Limited Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
NeoGenomics, Inc. logo
NEO
NeoGenomics, Inc.
$424M
$16.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
YD Bio Limited Ordinary Shares logo
YDES
YD Bio Limited Ordinary Shares
$436M
$6.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — NEO vs YDES

growth of $100 · dividends reinvested · last 1y
NEO +264.4% (+264.4%/yr)YDES -40.9% (-40.9%/yr)NEO compounded faster over this window
Log scale — wide-divergence pair
101001kStart $1002026$364$59
NEO YDES

NEO vs YDES: by the numbers

  • •YDES is the larger company ($436M vs $424M market cap).
  • •Both run net losses; NEO's is the smaller (-6.77% vs -1392.61% net margin).

Metrics side by side

Valuation

MetricNEOYDES
Forward P/E90.32N/A
P/S ratio0.55N/A
P/B ratio0.54N/A

Profitability

MetricNEOYDES
Gross margin42.92%-7.06%
Operating margin-8.63%-883.31%
Net margin-6.77%-1392.61%
ROE-6.60%-66.49%
ROIC-5.29%N/A

Growth (annualized)

MetricNEOYDES
Revenue CAGR (5Y)9.41%N/A
Total return CAGR (5Y)-15.14%N/A

Go deeper

Full NEO analysisFull YDES analysisInteractive comparison tool

Dig into the metrics

NeoGenomics ROEYD Bio Limited Ordinary Shares ROENeoGenomics operating marginYD Bio Limited Ordinary Shares operating marginNeoGenomics revenue growthYD Bio Limited Ordinary Shares revenue growthNeoGenomics free cash flowYD Bio Limited Ordinary Shares free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.